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Abstract: Expression of miRNAs in Neuroendocrine Neoplasms (NEN) is poorly characterized. 
We therefore wanted to examine the miRNA expression in Neuroendocrine Tumors (NETs), 
and identify their targets and importance in NET carcinogenesis. miRNA expression in six 
NEN primary tumors, six NEN metastases and four normal intestinal tissues was 
characterized using miRNA arrays, and validated by in-situ hybridization and qPCR. Among 
the down-regulated miRNAs miR-129-5p and the let-7f/let-7 family, were selected for 
further characterization. Transfection of miR-129-5p inhibited growth of a pulmonary and 
an intestinal carcinoid cell line. Analysis of mRNA expression changes identified EGR1 and 
G3BP1 as miR-129-5p targets. They were validated by luciferase assay and western blotting, 
and found robustly expressed in NETs by immunohistochemistry. Knockdown of EGR1 and 
G3BP1 mimicked the growth inhibition induced by miR-129-5p. let-7 overexpression 
inhibited growth of carcinoid cell lines, and let-7 inhibition increased protein content of  
the transcription factor BACH1 and its targets MMP1 and HMGA2, all known to promote 
bone metastases. Immunohistochemistry analysis revealed that let-7 targets are highly 
expressed in NETs and metastases. We found down-regulation of miR-129-5p and the let-7 
family, and identified new neuroendocrine specific targets for these miRNAs, which 
contributes to the growth and metastatic potential of these tumors. 
Keywords: neuroendocrine tumors; cancer; miR-129-5p; let-7; EGR1; G3BP1; HMGA2; 
BACH1; MMP1 
 
1. Introduction 
Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (GEP-NEN) are generally slow growing 
tumors originating from neuroendocrine cells in the gastro-intestinal tract and pancreas [1]. According 
to the WHO 2010 classification [2] GEP-NEN can be divided into two groups—the well differentiated 
Neuroendocrine Tumors (NETs) and the poorly differentiated Neuroendocrine Carcinomas (NECs).  
The NETs are further separated according to proliferative activity (Ki-67 index and mitotic counts) into  
NET-G1 (equivalent to carcinoid) and NET-G2. The NECs are G3 tumors (NEC-G3) and subtyped into 
small cell and large cell neoplasms. However, a deeper knowledge about the genetic changes leading to 
the development of carcinoid tumors is still lacking [1] thereby distinguishing GEP-NENs from the 
majority of cancer diseases of which there has been a substantial increase in knowledge [3]. 
One of the hallmarks of cancer cells is their ability to sustain chronic proliferation [4]. Aberrant 
growth signals independent of growth factor stimuli can be relayed by the RAS-MAPK (Mitogen 
Activated Protein Kinase) pathway [5]. RAS belongs to a family of small GTPases and acts as a molecular 
switch cycling between the active GTP-bound—and the inactive GDP-bound form [6]. RAS signaling is 
attenuated by GTPase activating Proteins (GAPs) [7]. Ras GTPase-activating protein-binding protein 1–3 
(G3BP1-3) binds the RasGAP and is important for transducing RAS signals in a MAPK-independent 
manner [8]. Besides interaction with RASGAP, G3BP1 also has endonuclease activity and seems to 
regulate stability of mRNAs adding yet another layer of growth control [9,10]. Activation of MAPK 
increases the expression of the Early Growth Response 1 (EGR1) transcription factor which in turn is 
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linked to key cancer processes such as growth and cell survival [11]. In carcinoids MAPK activation 
leads to increased tumor cell migration [12]. In breast cancers, inhibition of MAPK suppresses invasion 
and metastasis in part by increasing let-7 expression, which leads to suppression of the let-7 targets  
High-mobility group AT-hook 2 (HMGA2) and BTB-and CNC homology 1 leucine zipper transcription 
factor (BACH1) [13,14]. 
Growth signals are also controlled by microRNAs (miRNAs) which are short (18–25 nucleotides) 
non-coding RNAs [15]. miRNAs regulate protein synthesis by either degrading specific mRNA or by 
translation repression [16]. Because a single miRNA can target multiple mRNAs, one miRNA can regulate 
several cellular processes [17,18]. Malignant transformation of cells is associated with altered expression 
of miRNAs [17,18]. We identified two down-regulated miRNAs in NETs and metastases, characterized 
their actions in vitro and identified some of their targets in order to understand how dysregulation of 
these miRNAs contributes to NET carcinogenesis. 
2. Experimental 
2.1. Clinical Samples 
Tissues from 9 patients in total with 6 samples from small intestinal NET (G1+G2), 6 samples from 
metastasis and 4 samples from normal tissue samples (normal tissue was resected between 5–10 cm 
away from the tumor site) were obtained from patients undergoing surgery for carcinoid tumors at the 
Department of Surgical Gastroenterology, Rigshospitalet (see Supplementary Table 1 patients 1–9).  
The inclusion took place from 2008 to 2009 and the study was approved by the regional scientific ethical 
committee (journal number 01 313726) and signed, informed consent was obtained from all participants. 
Immediately after tumor resection, biopsies were placed in RNAlater® (Applied Biosystems, Carlsbad, 
CA, USA) for overnight incubation. Samples were subsequently stored at 80 °C until RNA extraction. 
One challenge of identifying miRNA differentially regulated between normal gastro-intestinal endocrine 
cells and gastro-intestinal neuroendocrine tumor/metastasis is obtaining a proper control. Neuroendocrine 
cells are normally intercalated between the absorptive cells lining the intestines, however, isolating these 
cells is difficult, and we therefore used normal tissue taken from the same patient from an area close to 
the tumor site knowing that this may not completely reflect the normal non-malignant cellular processes 
in the endocrine cells. 
2.2. Cell Culture 
The human pulmonary carcinoid cell line NCI-H727 (ATCC, Manassas, VI, USA) was grown  
in RPMI-1640 Glutamax (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS (Invitrogen), 
penicillin 100 U/mL and streptomycin 100 μg/mL (Invitrogen), 1 mM Sodium Pyruvate (Invitrogen) 
and kept at 37 °C with 5% CO2. CNDT2 is a human small intestinal carcinoid cell line kindly provided 
by Lee M. Ellis M.D. Anderson Center Texas USA [19] and kept in DMEM/F12 with 15 mM HEPES 
(Life Technologies, Carlsbad, CA, USA) supplemented with 10% FBS (Th. Geyer GmbH, Stuttgart, 
Germany), penicillin 100 U/mL and streptomycin 100 μg/mL (Life Technologies), 5 mL Sodium pyruvate 
100 mM (Sigma, St. Louis, MO, USA), 5 mL MEM NEAA 100× (Life Technologies), 5 mL  
L-Glutamine 200 mM 100× (Life Technologies) and 10 ng/mL NGF (Life Technologies) and kept at  
Genes 2015, 6 4
 
 
37 °C with 5% CO2. The human kidney carcinoma cell line HEK293 (ATCC) was grown in DMEM (Gibco) 
with 10% FBS (Invitrogen), 100 U/mL penicillin and 100 g/mL streptomycin (Invitrogen) and incubated 
at 37 °C with 5% CO2.  
2.3. RNA Extraction 
Total RNA was extracted using Trizol reagent (Invitrogen,) according to the manufacturer’s 
specifications. The RNA concentration was measured on the NanoDrop (Thermo Fisher Scientific, 
Waltham, MA, USA) and the RNA integrity was determined using the Agilent 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA, USA).  
2.4. miRNA Microarray Analyses 
1200 ng of total RNA from tumors, metastasis or normal tissues were used for labeling per array.  
For a common reference pool 1200 ng of total RNA from all the tissues together were mixed and 
hybridized to Invitrogen NCode Multi-Species miRNA Microarray V3 in a Maui hybridization station 
(Biomicro Systems Inc., Salt Lake City, UT, USA) and run as a two color experiment labeled using 
Invitrogen’s Ncode Rapid miRNA Labeling System according to the manufacturer’s specifications using 
the [Cy 3] color reagent for the tissue samples and the [Cy 5] color reagent for the common reference 
pool. For each run a mix of tumor, metastases and normal tissues were labeled to avoid batch variation. 
Hybridized slides were scanned in an Agilent DNA microarray scanner (Agilent Technologies) and 
images of spot intensities were converted to numerical values by GenePix Pro 6.0. The Bioconductor 
package limma was used to normalize the data and to perform the analysis of differential expression. 
The p-values were adjusted for multiple testing using the Benjamini-Hochberg method. Four biological 
replicates were used for each comparison. Data will be deposited at ArrayExpress upon acceptance. 
Based on the data obtained from the miRNA arrays, miRNAs for further studies were selected on fold 
change, p-value (p-value < 0.05) and knowledge about the miRNAs where available. 
2.5. qPCR 
miRNA expression was assessed using Taqman miRNA assays (Applied Biosystems) for  
hsa-miR-129-5p, hsa-let-7a and hsa-let-7c. For normalization of the miRNA expression data the geometric 
mean of hsa-miR-191 and RNU-44 were used [20]. Primer sequences for target validation are listed in 
Supplementary Table 2. 
Reverse transcription reactions are performed using the TaqMan MicroRNA Reverse Transcription 
Kit (Applied Biosystems) and run on the ABI PRISM 7900 HT Sequence Detection System (Applied 
Biosystems).  
2.6. In Situ Hybridization  
Formalin-fixed and paraffin-embedded (FFPE) tissue samples of 5 carcinoid tumors were obtained from 
the Department of Pathology (Rigshospitalet, Copenhagen, Denmark). A double-DIG-labeled miR-129-5p 
LNA (Exiqon, Vedbæk, Denmark) probe sequence GCAAGCCCAGACCGCAAAAAG RNA-Tm  
83 °C was used for detection as described [21]. Sections were counterstained with Nuclear Fast Red. 
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2.7. Immunohistochemistry 
Immunohistochemical staining of FFPE slides of 5 NETs (the same as the ones used for miR-129-5p 
in situ hybridization) was performed using primary antibodies against EGR1 (Abcam, Cambridge,  
UK dilution 1:200) and G3BP1 (Abcam; dilution 1:100). Immunohistochemical staining of paired tumor 
and metastasis tissue from 5 patients (not the same as for EGR1 and G3BP1, see Supplementary Table 1, 
patients 10–14) was performed using primary antibodies against BACH1.3 (Abcam; dilution 1:50), 
MMP-1/8 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA dilution 1:50) and HMGA2 (Cell Signaling 
Beverly, MA, USA, dilution 1:100). Sections were exposed to an antigen retrieval procedure in Target 
Retrieval Solution High pH (Dako, Glostrup, Denmark) except for HMGA2 where the antigen retrieval 
was done in Citrate buffer (Sigma) at 98 °C for 15 min, before being incubated with primary antibody for 
1 h at room temperature or overnight for HMGA2, followed by secondary antibody (EnVision + Dual Link, 
Dako) for 30 min at room temperature. After the diaminobenzidine reaction for 10 min at room temperature 
(liquid DAB + substrate–chromogen system, DakoCytomation), all sections were counterstained with 
hematoxylin & eosin.  
2.8. Transfection Studies and Cell Growth Analyses 
Four × 106 NCI-H727 or 150 × 103 CNDT2 cells were seeded and used for each transfection.  
To 965 μL Opti-MEM (Invitrogen) 10 μL Negative control 1, 2 or siGLO (Thermo Fisher Scientific)/miRNA 
-miR-129-5p, hsa-let-7-f (Applied Biosystems) hsa-let-7 family inhibitor LNA (Exiqon) or siRNA 
FlexiTube GeneSolution for EGR1 and siRNA FlexiTube GeneSolution for G3BP1 (Qiagen, Hilden, 
Germany) is added to a final concentration of 50 nM in 5 mL together with 25 μL Turbofect transfection 
reagent (Fermentas, Leon-Rot Germany) and left to incubate for 15–20 min at RT before being added 
drop-wise to the cells. For western blot studies dishes were harvested 12, 24, and 48 h after transfection. 
For growth analyses 2 × 106 cells were seeded and the media and transfection mix volume was halved. 
Cells were harvested 24 h after transfection and 40 × 103 cells (NCI-H727) or 15 × 103 cells (CNDT2) 
were seeded in each well into E-plates for use in the xCELLigence analyzer (Roche/ACEA, San Diego, 
CA, USA) for proliferation study. Briefly, the xCELLigence analyzer, which is an electronic cell sensor 
array technology, allows label-free and real-time monitoring of cell proliferation. The presence of the 
cells on top of the electrodes will affect the local ionic environment at the electrode/solution interface, 
leading to an increase in the electrode impedance. The more cells are attached on the electrodes,  
the larger the increases in electrode impedance [22,23]. The difference in cell number seeding for growth 
assays are due to differences in size and proliferative rate between the two cell lines. 
2.9. mRNA Microarray Analysis 
NCI-H727 and CNDT2 cells were transfected with 50 nM of miR-129-5p duplexes with siGLO 
siRNA used as a negative control. Total RNA was extracted 24 h post-transfection. Affymetrix  
microarray analysis HG-U133 Plus 2.0 human (Affymetrix, Santa Clara, CA, USA) was performed at  
the Microarray Center (Rigshospitalet, Copenhagen, Denmark). Experiments were run in triplicates. Data  
will be deposited at ArrayExpress. The microarray expression data was processed using the “affy” 
package in BioConductor [24]. Probe set intensities were summarized and quantile normalized using the 
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BioConductor RMA package. Differential expression was determined per probe set using a t-test.  
The probe sets were mapped to Ensembl transcripts (version 49) using mappings provided at BioMart. 
Probe sets that mapped to two different Ensembl genes were discarded.  
2.10. Evaluating Global Down-Regulation of microRNA Target Genes 
The 3’UTRs, 5’UTRs and coding sequences of the transcripts were scanned for matching 6mer, 7mer 
and 8mer miRNA seed sites (complementary to position 2–7, 2–8, and 2–9 of the miRNA). Global analysis 
of miRNA target down-regulation was evaluated using the longest 3’UTR sequence per gene to avoid 
bias introduced by genes with many transcript isoforms. We discarded transcripts with 3’UTR sequences 
shorter than 50 nt. To globally evaluate if miRNA target genes were down-regulated after miRNA 
transfection, we tested the null hypothesis that the expression change distribution of miRNA targets 
(having a 7mer target site) were equal to the distribution of all expressed genes without predicted target 
sites using the non-parametric Wilcoxon rank-sum test. A similar approach was used to evaluate  
down-regulation of genes with miRNA target sites in coding regions and 5’UTRs of mRNAs. 
2.11. Statistical Assessment of 3'UTR Words Correlated with mRNA Down-Regulation 
We used a previously published non-parametric rank-based statistic to assess the correlation of word 
occurrences in 3’UTRs and the change in gene expression after miRNA transfection [25,26]. Genes were 
sorted by expression change induced by transfection of miR-129-5p and the correlation with down-regulation 
was tested for all words of length 5–7 (N = 21 504). 
2.12. Gene Set Enrichment Analysis 
We examined if the genes differentially expressed upon miR-129-5p transfection were enriched  
in specific GO, KEGG or PFAM terms. The lists of genes with Benjamini-Hochberg adjusted p-values 
below 0.05 were checked for enrichment using GOstats package from Bioconductor. 
2.13. 3'UTR Luciferase Assay 
The 3'UTR for Egr1 and G3bp1 were amplified from human genomic DNA and cloned  
into the pmiR-report luciferase reporter plasmid generating pmiR-report-EGR1—3'UTR and  
pmiR-report-G3BP1-3'UTR. Plasmids containing mutated seed recognition sequence were subsequently 
generated. To exclude the actions of any endogenous miRNAs the assay was performed in the HEK293 
cell line (ATCC) since the overall content of miRNAs in this particular cell line is very low [27]. One hundred 
× 103 cells were seeded in 24 well plates and transfected the next day after standard procedure with a 
transfection mix consisting of 100 ng pmiR construct, 6.25 ng Renilla, 1 μL Turbofect, 1 μL pre-miR to a 
final concentration of 5 nM and Optimem ad 100 μL. The next day cells were lysed in Passive Lysis 
Buffer (Promega, Madison, WI, USA), vortexed 30 min and centrifuged 10 min. Thirty μL supernatants 
were transferred to white 96 well plates and signals from the plasmid constructs were measured and 
analyzed by using the Dual-Luciferase Reporter Assay System (Promega) and the Glomax 96 micro plate 
luminometer (Promega) according to the manufacturer’s specifications. 
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2.14. Western Blotting 
Samples were run on a Clear Page 4%–20% denaturing gel (C.B.S. Scientific, San Diego, CA, USA). 
By using the iBlotting (Invitrogen) system, proteins were transferred to a membrane and blocked in 5% 
w/v milk/0.01% w/v Tween-20/PBS incubated with primary antibody, either EGR1 ab55160, G3BP1 
ab39533 or BACH1 ab54814 (Abcam), MMP1 sc30069 (Santa Cruz Biotechnology Inc., Dallas, TX, 
USA), HMGA2 8179 (Cell Signaling) or Anti-Histone H3 05-499 (Millipore, Billerica, MA, USA) 
overnight and incubated with secondary antibody for 1 h. ECL SelectTM Western Blotting Detection 
Reagent (GE Healthcare Life Sciences, Uppsala, Sweden) was added to the membrane for 2 min.  
The luminescent signal present on the membrane was captured by a Fuji Film Las1000 Luminescent 
Image Analyzer Model LAS1000plus IDX2 using the Image Reader LAS1000 Pro v.2.5 and Image Gauge 
v.4.0 software captured the luminescent signal present on the membrane and was used for signal 
quantification. All western blots were repeated 3–5 times and with similar results When transfecting 
cells with a miRNA the target was down-regulated by quantification or up-regulated when transfecting 
cells with a miRNA-inhibitor. Only a representative blot is shown. 
2.15. Statistical Analyses 
Students’ unpaired t-test was used and differences with a p  0.05 were considered significant and 
indicated by *. Unless otherwise stated results are given as median ± SD. 
3. Results 
3.1. miR-129-5p is Down-Regulated in Neuroendocrine Tumors and the let-7 Family is  
Down-Regulated in Neuroendocrine Tumor Metastases 
We used miRNA array to identify miRNAs that are differentially regulated in tumors and metastases. 
Comparing NET primary tumors and metastases to the adjacent normal tissues we found that 48 out of 
a total of 1174 miRNAs were differentially expressed. Of these, 18 were down-regulated and 30 up-regulated 
(p-value < 0.05) (Supplementary Table S3). Based on fold-changes and p-values of the down-regulated 
miRNAs, miR-129-5p was selected for further analysis (Table 1).  
To associate miRNA changes with tumors and metastasis, we compared metastases and normal 
tissues and metastases and tumor tissues. In metastasis vs. normal tissue we found 145 miRNAs 
differentially expressed—77 down-regulated and 68 up-regulated (p-value < 0.05) (Supplementary Table 3). 
In tumor vs. metastasis 163 differentially expressed miRNAs—80 down-regulated and 83 up-regulated  
(p-value < 0.05) were identified. Noticeably, 8 members of the let-7 family (let-7 –a, -b, -c, -d, -e, -f, and -i) 
were down-regulated in both comparisons, underlining the let-7 family’s role in metastasis (Table 1).  
To validate the reduced expression in carcinoids we performed qPCR on independent samples from laser 
capture micro dissected tissue from blocks from a different patient group also diagnosed with NETs and 
in-situ hybridization analysis for miR-129-5p (Figure 1a,b) and for the let-7 family (Figure 1c) on the 
same patient group as the qPCR.  
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Table 1. Differentially regulated miR-129-5p and let-7. 
T + M vs. N Log FC FC p-value 
hsa-miR-129-5p 1.3 0.4 0.01 
hsa-let-7a 1.7 0.3 0.002 
hsa-let-7c 1.7 0.3 0.001 
hsa-let-7b 1.5 0.3 0.0003 
hsa-let-7d 1.5 0.3 0,003 
hsa-let-7e 1.4 0.4 0.002 
hsa-let-7f 1.4 0.4 0.003 
hsa-let-7g 1.1 0.5 0.01 
hsa-let-7i 1.3 0.4 0.001 
M vs. N Log FC FC p-value 
hsa-let-7a 1.7 0.3 0.002 
hsa-let-7c 1.7 0.3 0.001 
hsa-let-7b 1.5 0.3 0.0003 
hsa-let-7d 1.5 0.3 0.003 
hsa-let-7e 1.4 0.4 0.002 
hsa-let-7f 1.4 0.4 0.003 
hsa-let-7g 1.1 0.5 0.01 
hsa-let-7i 1.3 0.4 0.001 
M vs. T Log FC FC p-value 
hsa-let-7a 0.03 0.8 0.3 
hsa-let-7c 0.02 1.0 0.9 
hsa-let-7b 0.3 0.8 0.3 
hsa-let-7d 0.2 0.9 0.6 
hsa-let-7e 0.1 0.9 0.6 
hsa-let-7f 0.1 0.9 0.8 
hsa-let-7g 0.1 0.9 0.8 
hsa-let-7i 0.02 1.0 0.9 
miRNAs are chosen on the basis of fold change and p-value. Only miR-129-5p and let-7a and c have  
been verified by qPCR analysis, the rest of the let-7 family members are included to show that the whole  
family is lost. T + M vs. N and T vs. M denote Tumor and Metastasis vs. Normal tissue and Tumor vs.  
Metastasis respectively. 
3.2. miR-129-5p Inhibits Growth of the Carcinoid Cell Lines NCI-H727 and CNDT2 
NETs usually occur in the gastro-intestinal tract and lung [28], we therefore used both a pulmonary 
carcinoid cell line, NCI-H727, and a small intestinal carcinoid cell line, CNDT2, as model systems for 
NETs and for in vitro investigation of the effect of the identified miRNAs. Given that growth is one of 
the hallmarks of cancer [4] we examined how over-expression of miR-129-5p affected the growth of 
cells in vitro and found that it inhibited the growth of both of the pulmonary carcinoid cell line NCI-H727 
and the small intestinal CDNT2 carcinoid cell line (Figure 2a,b) indicating that both cell lines are good 
model systems for NETs and that at least some of the biological processes determining growth in these 
cell lines are identical.  
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Figure 1. The expression of miR-129-5p and let-7 are down-regulated in neuroendocrine 
tumors. (a,b) qPCR analysis and in situ hybridization showed little expression of  
miR-129-5p in NETs compared to the adjacent normal tissue (scale bar 100 μm) consistent 
with the qPCR results. Arrows with N and T denote Normal and Tumor tissue respectively. 
The average expression of the miRNAs is normalized to the geometric mean of RNU44 and 
miR-191; (c) qPCR analysis of let-7a and let-7c showed a clear down-regulation in tumors 
compared to matched control tissue and metastases compared to tumors respectively, 
although the down-regulation was not significant for let-7c.* = p < 0.05. 
To further describe the biological actions of miR-129-5p, we characterized its mRNA targets.  
We found that mRNAs with predicted miRNA target sites (7mer seed site) in the 3’UTR were 
significantly down-regulated compared to mRNAs without predicted target sites after transfection of 
miR-129-5p in both cell lines (p = 5.5e–23, two-tailed Wilcoxon rank-sum test) (Figure 2c,d). Unbiased 
word analysis of all oligonucleotides (words) of length 5–7 demonstrated that the miR-129-5p 7mer seed 
site was the 3’UTR word most correlated with down-regulation in the cell lines (Figure 2e,f). Gene 
Ontology (GO) term enrichment analysis showed that miR-129-5p mainly controlled pathways related 
to nucleotide metabolism and RNA binding in the NCI-H727 cell line (data not shown). 
3.3. miR-129-5p Targets EGR1 and G3BP1 in Carcinoid Cell Lines NCI-H727 and CNDT2 
EGR1 and G3BP1 were among the most down-regulated targets following miR-129-5p  
over-expression in both the NCI-H727 and CNDT2 cell line and were therefore selected for further analyses 
(Supplementary Table S4). EGR1 is a transcription factor [29] and G3BP1 is involved in both RNA 
metabolism and Ras activation [9]. There is one target sequence for miR-129-5p in the 3'UTR of EGR1 
and two in that of G3BP1. Direct interaction of miR-129-5p with the target gene 3' UTRs was demonstrated 
by luciferase assay and showed a significant reduction in signals. For G3BP1 miR-129-5p binding to the 
distal target sequence leads to a greater inhibition of the luciferase signal than binding to the proximal 
target sequence, and both sites acted synergistically. The finding that the most effective site resides near 
the end of the 3’UTR of G3BP1 and that both sites were associated with greater mRNA destabilization 
in our transfection experiments has also been observed for other mRNAs [30] (Figure 3a,b,e,f).  
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Figure 2. miR-129-5p inhibits growth of carcinoid cell lines. (a,b) NCI-H727 and CNDT2 
cells were transfected with miR-129-5p or a control and the growth was examined using  
the xCELLigence system. A marked growth inhibition is seen when cells are transfected 
with miR-129-5p. For NCI-H727 cells the slopes are 5.6 × 102 h1 (Control) compared to 
3.7 × 102 h1 (miR-129-5p). For the CNDT2 cells the slopes are 6.0 × 101 h1 (Control) 
compared to 4.6 × 101 h1; (c–f) The global changes in gene expression in NCI-H727 and 
CNDT2 cells respectively following transfection of miR-129-5p were determined by 
microarray. Subsequent word analysis of the down regulated transcripts showed an enrichment 
of transcripts containing the 7-mer targets of words. 
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Figure 3. EGR1 and G3BP1 are targets of miR-129-5p. (a,e) Direct interaction between the 
miR-129-5p and its target sites in EGR1 and G3BP1 3’UTRs was determined using luciferase 
assays. The miR-129-5p sequence is followed by the wild type EGR1 and G3BP1 3’UTR target 
sequences. At the bottom the mutated target sites are shown with changes in the 4 central 
nucleotides that should abolish binding of miR-129-5p to the two targets; (b,f) Transfection 
of miR-129-5p significantly reduced the luciferase activity of constructs containing the wild 
type but not mutated 3’UTRs constructs, ** p < 0.01, *** p < 0.001 (c,d,g,h) Transfection of 
NCI-H727 (c,g) and CNDT2 (d,h) cells respectively with miR-129-5p leads to a reduction 
of EGR1 and G3BP1. Protein signals are quantified and values are below each lane, only 
representative blots are shown and densitometry below each lane represents that blot.  
The bars represent the combined densitometry results for the western blot replicates, and 
statistic significances, if any, are indicated above. 
Western blot analyses confirmed that the expression of the EGR1 and G3BP1 proteins were reduced 
after re-introduction of miR-129-5p to both carcinoid cell lines (Figure 3c,d,g,h). This confirms both EGR1 
and G3BP1 as new bona fide miR-129-5p targets. 
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3.4. EGR1 and G3BP1 are Up-Regulated in Neuroendocrine Tumors and Promote Growth in 
Carcinoid Cell Lines 
Given the reduced expression of miR-129-5p in NETs we examined the expression of EGR1  
and G3BP1 in NETs and we found the two genes highly expressed in NETs by immunohistochemistry 
(Figure 4a).  
 
Figure 4. EGR1 and G3BP1 are present in neuroendocrine tumors and important for  
the growth in a carcinoid cell line. (a) The two miR-129-5p targets EGR1 and G3BP1 are 
robustly expressed in NETs compared to the adjacent normal tissue where expression of the 
two targets are significantly lower as shown by immunohistochemistry. Immunohistochemistry 
was performed on all the tumors used in the qPCR analysis for miR-129-5p, for simplicity 
only one is shown here (scale bar 100 μm) EGR1 insert shows nuclear staining for EGR1 in 
NETs shown in 600× magnification; (b,c) siRNA knock down of either EGR1 or G3BP1 
markedly inhibits the growth of the NCI-H727 cells and CNDT2 cells respectively.  
The slopes of the growth curves are for NCI-H727 4.64 × 102 h1 (control) compared to  
3.58 × 102 h1 (EGR1) and 3.30 × 102 h1 (G3BP1). When looking at the CNDT2 cell line 
the slopes of the growth curves are 5.68 × 101 h1 (Control) compared to 4.67 × 101 h1 (EGR1) 
and 4.96 × 101 h1 (G3BP1). 
To characterize the biology of EGR1 and G3BP1 in NETs, we examined their importance for growth 
of carcinoid cell lines. We found that knock down of EGR1 and G3BP1 inhibited the growth of carcinoid 
cell lines compared to controls (Figure 4b,c). This suggests that at least some of miR-129-5p’s biological 
actions in NETs is exerted though control of EGR1 and G3BP1. 
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3.5. The let-7 Family is Involved in the Neuroendocrine Tumor Metastatic Process by Targeting 
HMGA2 and BACH1 
Almost half of the patients with NETs have regional or distant metastases at the time of  
diagnosis [31]. HMGA2 is a chromatin remodeling factor and BACH1 is a transcription factor which 
transcribes the Matrix Metalloproteinase 1 (MMP1). All three acts synergistically to induce bone 
metastasis and HMGA2 and BACH1 are key targets for let-7 inhibition and highly involved in the 
metastatic process [14,32]. We therefore examined how re-introducing the expression of a let-7 family 
member affected the growth of carcinoid cell lines. Transfection with let-7f inhibited the growth of both 
the carcinoid cell lines (Figure 5a,b).  
 
 
Figure 5. Cont. 
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Figure 5. let-7 inhibits growth of a carcinoid cell lines and targets genes involved in the 
metastatic event. (a,b) NCI-H727 and CNDT2 cells respectively were transfected with let-7f 
or a control and the growth was examined using the xCELLigence system. A marked growth 
inhibition is seen when cells are transfected with let-7f. For NCI-H727 cells the slopes are 
5.6 × 102 h1 (Control) and 3.66 × 102 h1 (let-7f); for the CNDT2 cells the slopes are  
3.3 × 101 h1 (Control) and 2.7 × 101 h1 (let-7f); (c,d) Transfection of NCI-H727 and 
CNDT2 cells with a let-7 family inhibitor leads to a marked increase in BACH1, MMP1 and 
HMGA2 protein signals (see the quantified values below each lane). Only representative blots 
are shown and densitometry below each lane represents that blot. The bars represent the 
combined densitometry results for the western blot replicated and statistic significances, if 
any, are indicated above; (e) Immunohistochemistry of NETs and paired metastasis show a 
robust expression of BACH1, MMP1 and HMGA2, for comparison immunohistochemistry 
for BACH1, MMP1 and HMGA2 was also performed in normal intestine far right panel 
(scale bar 100 μm). HMGA2 inserts show nuclear staining for HMGA2 in NETs shown at 
600× magnification. 
Secondly we examined the biological consequence of reduced let-7 expression in NETs and 
metastasis by western blot analyses and immunohistochemistry on paired FFPE tumor and metastases 
tissues for HMGA2, BACH1 and MMP1. Western blot analysis showed an increase in cellular content  
of the HMGA2, BACH1 and MMP1 proteins (we assume that the modest increase seen in MMP1 in 
comparison to BACH1, might be due to other regulatory processes in the different tissues and cell lines 
than that of BACH1) when a let-7 family inhibitor was transfected into the carcinoid cell lines confirming 
the two proteins as genuine targets of let-7 (Figure 5c,d). The immunohistochemistry showed a robust 
expression of the three proteins in the NET tumor and paired metastatic tissues (Figure 5e), which, to 
the best of our knowledge, is the first time all three proteins have been demonstrated in neuroendocrine 
tumors and their metastases. 
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4. Discussion 
We have shown that the expression of miRNAs is deregulated in small intestinal NETs (G1+G2) and 
found indication that the number of de-regulated miRNAs seems to increase as the tumors metastasize. 
Our observation parallels the report by Lloyd and colleagues who recently also found aberrant miRNA 
expression in NETs [33]. They examined 95 miRNAs and we found some of the same, but not all, to be 
down- or up-regulated. The difference between our findings and those of Lloyd and colleagues can be 
attributed to the difference in the miRNA included in the different assays and technical differences 
between the platforms used (Invitrogen miRNA microarray, this study) and the Cancer MicroRNA qPCR 
Array Kit [33–35]. It could also be attributed to the relatively small number in sample size in our 
experiments. Robust bioinformatics is best done on paired samples and a larger group of samples; 
however we only had access to limited material. Therefore we carefully validated our results both in cell 
lines and in neuroendocrine tissue from patients. In addition miR-129-5p and the let-7 family are known 
to have an anti-proliferative and anti-metastatic effect in other cancers which makes them even more 
likely to be missing in neuroendocrine cancers [13,36].  
Access to suitable in vitro and in vivo model systems for carcinoid tumors are important for examining 
the biological impact of observations made from clinical samples. We found that that in terms of the 
response to miR-129-5p and let-7f manipulation both model cell lines (NCI-H727 and CDNT2) responded 
in a similar manner. Hence, we consider them good in vitro models of NET biology. 
We focused on miR-129-5p, which we found to be down-regulated in NETs. We found that transfection 
of miR-129-5p inhibited carcinoid cell growth. miR-129-5p has also been found down-regulated in 
gastric cancer [37], bladder cancer [38] and colorectal cancer [39]. In these tumors miR-129-5p was also 
shown to inhibit growth consistent with miR-129-5p being a tumor suppressor miRNA [40]. Global analysis 
of pathways affected by miR-129-5p showed that it primarily targeted RNA binding and nucleotide 
metabolism. We identified EGR1 and G3BP1, both known to regulate these processes as novel targets 
for miR-129-5p. 
In some cancers EGR1 inhibits growth [41] where as in others EGR1 is associated with tumor 
progression, for instance in prostate and gastric cancer which possess endocrine components [42,43]. 
We found increased expression of EGR1 in the NETs and that knockdown of EGR1 inhibited growth  
of the carcinoid cells. Recently, Edtfeld et al. have associated increased EGR1 expression with NET 
progression [44]. The transcription of EGR1 is controlled by the MAPK signaling pathway through 
phosphorylation and activation of transcription factors of the ETS like transcription factor (ELK-1) 
family by Extracellular-signal-Regulated Kinases (ERK1/2), p38MAPK and/or c-Jun N-terminal kinases 
(JNK) [45,46]. A particular feature of NENs are that they have elevated levels of Ras-related Protein 1 
(RAP1) and Serine/threonine-protein kinase B-raf (B-RAF) [47] which in turn activates MAPK thereby 
enabling the high expression levels of EGR1 leading to increased tumor progression. 
The Extracellular-signal-regulated kinases (ERK) pathway can be activated by growth factors such 
as Epidermal Growth Factor (EGF) [48], and when activated by ERK and a subsequent induction of 
EGR1 exceeds a critical threshold, cells are permitted to enter the S phase and divide [49]. Thus, there 
seems to be a “digitization” of the biological response to a graded EGR1 expression signal. Although 
miRNAs mainly modulate gene expression, a reduction in miR-129-5p could be important for this 
mechanism as it would result in increased amounts of EGR1. Modulation of these signals may be 
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important for neuroendocrine carcinogenesis as for instance Epidermal Growth Factor Receptor (EGFR) 
signaling is important for neuroendocrine growth [50,51]. 
Moreover, we found G3BP1 to be a novel target of miR-129-5p. G3BP1 is over-expressed in  
NETs, which in this respect resemble other tumors such as colon, thyroid, breast, lung, and head-neck 
tumors [52]. Loss of G3BP1 leads to growth retardation [53] whereas over-expression promotes growth 
and migration [9,54]. G3BP1 acts as an effector of RAS as it only binds active RAS, thereby contributing 
to the signaling cascade via MAPK [55]. In many cancers mutations that activates RAS are driven by 
mutations in BRAF [56] but BRAF mutations are rare in NETs [57]. However, the activating protein RAP1 
is frequently expressed and the Raf proto-oncogene serine/threonine-protein kinase (RAF1) RAF1/BRAF 
signaling pathway is activated in NETs [47] making this pathway a putative therapeutic target. We showed 
that by inhibiting G3BP1 we can inhibit growth of carcinoid cells demonstrating that indeed this pathway 
is important in neuroendocrine carcinogenesis. Because miR-129-5p targets both G3BP1 and EGR1 we 
propose, that miR-129-5p is an important regulator of oncogenic signals in small intestinal NETs.  
We found the expression of many of the let-7 family members down-regulated in NETs metastases. 
The let-7 family consists of 13 family members [58] that are important for promoting cell-cycle exit and 
terminal differentiation [59]. In some cancers all or most members have been reported lost or down-regulated 
e.g., gastric cancer, lung cancer, and head and neck cancers [60]. In other cancers only a few specific 
members have been shown to be lost e.g., let-7b in melanoma [61]. Metastatic NENs seem to belong to 
the first group, though the biological differences between down-regulation of many or few let-7 members 
is poorly understood. We found that transfection of let-7f inhibited growth of carcinoid cells and that 
many of the let-7 targets involved in the metastatic process was up-regulated. In NENs and their metastases 
we found increased expression of HMGA2, BACH1 and its target MMP1. Some of the changes in miRNA 
expression associated with the metastatic process in NETs are similar to what has been seen when other 
tumors metastasize. Reduced expression/loss of let-7 has also been seen when for instance breast cancer [14], 
gastric cancer [62], colorectal cancer [63], and renal cancer metastasize [64]. HMGA2 over expression 
in itself is a hallmark for both benign and malignant tumors and also linked to a highly malignant 
phenotype with a poor prognostic index. The importance of particularly the let-7 family of miRNAs in 
suppressing HMGA2 is evident by the fact that multiple let-7 binding sites are in the 3’UTR of HMGA2. 
The correlation between let-7 down-regulation and HMGA2 over-expression in NETs previously shown 
by Rahmann et al. [60] suggests that the basis for metastasis is founded very early in the carcinogenesis of 
NETs and lasts until the tumor actually metastasizes. In addition there is a correlation between low  
let-7 expression in tumors with high HMGA1/2 expression and the grading stages of NETs where the 
high grade and highly invasive tumors also have high expression of HMGA1/2 and low let-7 expression. 
The same relationship is also seen with respect to tumor size [60,65]. 
The anti-tumorigenic effect of let-7 by targeting both HMGA2 and BACH1 is especially effective in 
abrogating bone metastasis in a breast cancer model where the two proteins share some but not all of the 
same target genes. Knocking down both BACH1 and HMGA2 suppressed metastatic invasion, homing and 
osteolysis [32], where knocking down only one of the two proteins did not suppress enough of the target 
genes in these pathways to prevent metastasis. In the past bone metastasis originating from NETs was 
considered rare since they usually metastasize to the liver, lymph node and lungs, however, they are 
becoming more and more prevalent due to both better and earlier detection and because of the longer 
survival of NET patients [28]. The mechanism behind bone metastasis from NETs has as of yet not been 
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fully elucidated, but the cooperation between some of the same key players, as in the breast cancer model, 
seems a definite possibility based on our results. The importance of recognizing the fact that NETs do 
metastasize to the bones lies in the fact that this can be used as a prognostic factor for overall survival [28]. 
5. Conclusions 
In conclusion we have shown that miRNAs are dysregulated in NETs and identified two of the  
down-regulated miRNAs in NETs, miR-129-5p and the let-7 family to have growth inhibitory effects. 
We identified two new targets EGR1 and G3BP1 for miR-129-5p and discovered a possible pathway for 
bone metastasis involving let-7 and its targets HMGA2 and BACH1. 
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